Institutional members access full text with Ovid®

Share this article on:

Vulvar Lichen Sclerosus: A Comparison of the Short-term Topical Application of Clobetasol Dipropionate 0.05% Versus Mometasone Furoate 0.1%

Murina, Filippo MD; Rehman, Subhia MD; Di Francesco, Stefania MD; Mantegazza, Valeria MD; Felice, Raffaele MD; Bianco, Vanda MD

Journal of Lower Genital Tract Disease: April 2015 - Volume 19 - Issue 2 - p 149–151
doi: 10.1097/LGT.0000000000000065
Original Articles: Vulva and Vagina

Objective: To compare the efficacy of the short-term application of clobetasol propionate 0.05% (CLB) and mometasone furoate 0.05% (MMF) in the treatment of vulvar lichen sclerosus (VLS).

Study Design: This study was a retrospective review of 96 women who were diagnosed with lichen sclerosus with a follow-up of at least 1 year. Of these 96 women, 47 were treated with the topical application of CLB and 49 were treated with the topical application of MMF. All patients received treatment for 8 weeks. The drug was administered once daily for 4 weeks and then twice weekly for another 4 weeks in combination with a moisturizing cream that was continued as maintenance therapy. Subsequently, a topical steroid was applied on an as-needed basis if symptoms recurred. Follow-up visits were scheduled at 3, 6, and 12 months. The primary endpoint was the clinical response of the patients.

Results: A mean of 77.3% of the patients were defined as responders at the 12-month observation, without any significant difference between the 2 treatment groups (CLB mean 73% vs MMF mean 81.6%, p = .2). A pronounced improvement in itching was observed after 3 months of treatment in the MMF group (p = .04), whereas the other symptoms were not significantly different between the 2 groups.

Conclusions: This study indicates that CLB 0.05% and MMF 0.1% in a short protocol regimen are effective, safe, and reliable treatments for VLS, with no significant difference between the 2 steroids in their efficacy. However, a moisturizing cream should be an integral part of the treatment.

Comparison of the short-term topical application of clobetasol dipropionate 0.05% versus mometasone furoate 0.1% in a short protocol regimen. No significant difference in the treatment for vulvar lichen sclerosus was found.

Outpatient Department of Vulvar Disease, V. Buzzi Hospital-ICP-University of Milan, Milan, Italy

The authors have declared they have no conflicts of interest.

Reprint requests to: Filippo Murina, MD, V. Buzzi Hospital, Via Castelvetro 32, Milan, Italy. E-mail:

Copyright © 2015 by the American Society for Colposcopy and Cervical Pathology